The questions behind a useful conversation.
From the pharmacy day to an industrial process or investment opportunity, these answers help you find a relevant starting point. They explain the work and its stage, leaving room for a detailed discussion when a programme connects with a decision you need to make.
What does NEUVIOR do, and how is the name pronounced?
NEUVIOR is a pharmaceutical research and technology company working across Medicines Intelligence, biomedical research and Resource Economics. PHARMORIS, the glioblastoma recurrence programme, ZYLON and PHARMORIS-ECO sit within that portfolio. Constellation is the proposed campus concept connecting research, enterprise and public discovery. Each programme has its own question and development stage; they should not be read as a single catalogue of available products.
NEUVIOR® is pronounced NOO-VWAHR, /nuːˈvwɑː(r)/. NEU expresses possibility and discovery; callings from within. VIOR expresses virtuosity and passion; the pursuit of excellence. The full definition is presented on About, alongside the phrase at the heart of the company: ingenuity, and the art of possibility. The name describes an ambition for what medicine has yet to become.
What is PHARMORIS, and what can I ask to see?
PHARMORIS is the Medicines Action Layer under controlled development and evaluation planning. Its proposition concerns the connection between evidence, accountable decisions, implementation and review. You can bring a recurring medicines-work problem and ask how a relevant capability or evaluation could be examined. The team would need to establish what can currently be demonstrated and what further development would be required.
A demonstration and a customer evaluation answer different questions. The first can show a function; the second needs a task, an existing comparison and appropriate measures. NICE (2022), evidence standards framework provides an external reference for evaluating digital-health evidence and value. It does not mean PHARMORIS has been assessed or endorsed by NICE. Any proposed access or commissioned work would have a separately agreed scope.
Is this relevant to a small pharmacy or only a large organisation?
A single independent owner can have a valuable decision problem, just as a pharmacy group, online provider, GP team, trust or commissioner can. The scale of the engagement should fit the question. A local service timetable, repeated referral clarification or an awkward review-preparation task can be a more useful starting point than a broad transformation programme. The audience pages explain several settings without claiming named customer relationships.
Bring the current approach, who owns the decision and what makes it difficult. The commercial discussion should distinguish staff capacity, provider contribution and consequences elsewhere in the system. More activity is not automatically more value. Any proposal should also say what would justify continuing and what finding would make further investment inappropriate, rather than assume that every exploratory conversation must become a pilot.
Can I access a treatment or join a clinical trial?
NEUVIOR is not currently offering an experimental treatment or recruiting people to a glioblastoma clinical trial. The biomedical programme is at scientific design and development-planning stage. Public research material explains questions and relevant published work; an external study or image should not be mistaken for a NEUVIOR clinical result. Your treating clinical team is the appropriate starting point for questions about personal treatment or suitable trials.
Researchers can discuss a defined question, methodology or future contribution, with study responsibilities and approvals agreed separately. For software, MHRA (2025), software and AI guidance informs intended-use and regulatory questions; it does not approve a NEUVIOR programme.
Are the campuses open, and what can an investor examine?
Constellation is a proposed campus model, with Scotland under consideration for a possible first destination. It is not presented as an operating science park. Its value proposition connects useful research infrastructure, enterprise space and public discovery. The long-term ambition for eight destinations by 2045 depends on evidence of demand, an appropriate operating model and a justified development and finance pathway.
An investor can ask about the decision sequence, prospective users, revenue hypotheses, development requirements and the evidence that would support a next-stage commitment. Research support belongs to its named programme and should not be interpreted as construction finance. The public concept is a starting point for investigating value, with any non-public discussion and proposed participation agreed separately.
What makes a useful first enquiry?
Tell us the programme, your setting and the decision you want to inform. A short description is enough; avoid sending confidential datasets through a general enquiry. We can discuss the relevant expertise and a bounded next step, with terms and responsibilities agreed before commissioning.
